Trial reportCancer discovery2013
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Trial report in Cancer discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 229 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)
"Phase II Study to Evaluate the Activity and Safety of Cabozantinib in Pretreated, Advanced RET-rearranged Non-small Cell Lung Cancer Patients: CRETA Trial"
Who cites it
229 citing papers in PubMed, 3 syntheses or guidelines pooled it, 470 citations in OpenAlex.
- CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.BMC medical imaging · 2017Pooled it
- The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.Cancer biology & therapy · 2015Pooled it
- Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Nature communications · 2014Pooled it
- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.The Lancet. Oncology · 2016Trial
- Trial
- Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell communication and signaling : CCS · 2025Review
- Artificial Intelligence-Based Model Exploiting Hematoxylin and Eosin Images to Predict Rare Gene Mutations in Patients With Lung Adenocarcinoma.JCO clinical cancer informatics · 2025Article
- N-glycans in lung tissue specimens: a prospective target for enhanced cancer diagnosis and prognosis.Journal of translational medicine · 2025Article
- RNA splicing: Novel star in pulmonary diseases with a treatment perspective.Acta pharmaceutica Sinica. B · 2025Review
- An accurate DNA and RNA based targeted sequencing assay for clinical detection of gene fusions in solid tumors.Scientific reports · 2025Article
- Remarkable response to low dose of selpercatinib in a patient withRespiratory medicine case reports · 2025Article
- The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients.Biochemical genetics · 2024Article
- Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.Cancers · 2024Article
- Prognostic and immunotherapeutic implications of bilirubin metabolism-associated genes in lung adenocarcinoma.Journal of cellular and molecular medicine · 2024Article
- Article
- Article
- Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.BMC cancer · 2024Article
- Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives.Frontiers in oncology · 2024Review
- The rapidly changing field of predictive biomarkers of non-small cell lung cancer.Pathology oncology research : POR · 2024Review
169 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
The discovery of RET fusions in lung cancers has uncovered a new therapeutic target for patients whose tumors harbor these changes. In an unselected population of non-small cell lung carcinomas (NSCLCs), RET fusions are present in 1% to 2% of cases. This incidence increases substantially, however, in never-smokers with lung adenocarcinomas that lack other known driver oncogenes. Although preclinical data provide experimental support for the use of RET inhibitors in the treatment of RET fusion-positive tumors, clinical data on response are lacking. We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508). Confirmed partial responses were observed in 2 patients, including one harboring a novel TRIM33-RET fusion. A third patient with a KIF5B-RET fusion has had prolonged stable disease approaching 8 months (31 weeks). All three patients remain progression-free on treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.